Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of nivolumab + ipilimumab or nivolumab + chemotherapy versus chemotherapy in untreated unresectable or metastatic urothelial cancer
jRCT2080223696Phase 3Completed
- Sponsor
- Ono Pharmaceutical
- Start
- Oct 2017
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, open-label trial of nivolumab, ipilimumab, gemcitabine, cisplatin and carboplatin in transitional cell carcinoma (TCC) (3 arms), sponsored by Ono Pharmaceutical. Started Oct 2017; status: completed.
02
Drugs
03
Conditions
transitional cell carcinoma (TCC)
Beyond the preview
Go deeper on jRCT2080223696.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223696.